Evidence map›Paper›PMID 36976427›Full record

ReviewJournal of molecular modeling2023

A compact review of progress and prospects of deep learning in drug discovery.

Huijun Li, Lin Zou, Jamal Alzobair Hammad Kowah, Dongqiong He, Zifan Liu, Xuejie Ding, Hao Wen, Lisheng Wang, Mingqing Yuan, Xu Liu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of molecular modeling, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Improved Prediction of Ligand-Protein Binding Affinities by Meta-modeling.Journal of chemical information and modeling · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Huijun LiCollege of Medicine, Guangxi University, Nanning, 530004, China.
Lin ZouCollege of Medicine, Guangxi University, Nanning, 530004, China.
Jamal Alzobair Hammad KowahCollege of Chemistry and Chemical Engineering, Guangxi University, Nanning, 530004, China.
Dongqiong HeCollege of Chemistry and Chemical Engineering, Guangxi University, Nanning, 530004, China.
Zifan LiuCollege of Medicine, Guangxi University, Nanning, 530004, China.
Xuejie DingCollege of Medicine, Guangxi University, Nanning, 530004, China.
Hao WenCollege of Chemistry and Chemical Engineering, Guangxi University, Nanning, 530004, China.
Lisheng WangCollege of Medicine, Guangxi University, Nanning, 530004, China.
Mingqing YuanCollege of Medicine, Guangxi University, Nanning, 530004, China.
Xu LiuCollege of Medicine, Guangxi University, Nanning, 530004, China. wendaoliuxu@163.com.ORCID http://orcid.org/0000-0002-5584-4521

Funding

Guangxi Innovation-Driven Development Special Fund Project GUANGXI AA18242040Guangxi Key Laboratory of Traditional Chinese Medicine Quality Standards Research guizhongzhongkai201703Guangxi Key Laboratory of Trusted Software, Guilin University of Electronic Technology No. kx201703Guangxi Key Research and Development Program GUANGXI AB18221121National Natural Science Foundation of China 22078073
6 · The paper itself

Abstract

backgroundDrug discovery processes, such as new drug development, drug synergy, and drug repurposing, consume significant yearly resources. Computer-aided drug discovery can effectively improve the efficiency of drug discovery. Traditional computer methods such as virtual screening and molecular docking have achieved many gratifying results in drug development. However, with the rapid growth of computer science, data structures have changed considerably; with more extensive and dimensional data and more significant amounts of data, traditional computer methods can no longer be applied well. Deep learning methods are based on deep neural network structures that can handle high-dimensional data very well, so they are used in current drug development.

resultsThis review summarized the applications of deep learning methods in drug discovery, such as drug target discovery, drug de novo design, drug recommendation, drug synergy, and drug response prediction. While applying deep learning methods to drug discovery suffers from a lack of data, transfer learning is an excellent solution to this problem. Furthermore, deep learning methods can extract deeper features and have higher predictive power than other machine learning methods. Deep learning methods have great potential in drug discovery and are expected to facilitate drug discovery development.

Indexed as

Deep LearningDrug DesignDrug DiscoveryMachine LearningMolecular Docking SimulationNeural Networks, ComputerDeep learningDrug designDrug discoveryDrug reactionDrug repositioningRecommendation system

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.